Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 July 2005, Vol. 106, No. 1, pp. 362-367.
Prepublished online as a Blood First Edition Paper on March 17, 2005; DOI 10.1182/blood-2005-01-0160.

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-01-0160v1
106/1/362    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macciò, A.
Right arrow Articles by Mantovani, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macciò, A.
Right arrow Articles by Mantovani, G.
Related Collections
Right arrow Neoplasia
Right arrow Red Cells
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

RED CELLS

Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia

Antonio Macciò, Clelia Madeddu, Daniela Massa, Maria C. Mudu, Maria R. Lusso, Giulia Gramignano, Roberto Serpe, Gian Benedetto Melis, and Giovanni Mantovani

From the Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy; the Department of Medical Oncology, University of Cagliari, Cagliari, Italy; and the Department of Obstetrics and Gynecology, University of Cagliari, Cagliari, Italy.


   Abstract
Top
 Abstract
Introduction
 Patients and methods
 Results
 Discussion
 References
 
Anemia occurs in more than 30% of patients with epithelial ovarian cancer before any surgery. High levels of proinflammatory cytokines and increased oxidative stress may contribute to the development of cancer-related anemia. We assessed a population of previously untreated patients with advanced epithelial ovarian cancer to evaluate whether there was a correlation between hemoglobin (Hb) and parameters of inflammation and oxidative stress, stage of disease, and performance status (PS). In 91 patients with epithelial ovarian cancer and 95 healthy women matched for age, weight, and height, levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines, leptin, reactive oxygen species (ROS), and antioxidant enzymes were assessed at diagnosis before treatment. The correlations between Hb, parameters of inflammation and oxidative stress, stage, and PS were evaluated. Hb levels were lower in patients with advanced epithelial ovarian cancer than in control subjects and inversely related to stage and PS. Hb negatively correlated with CRP, Fbg, interleukin 1{beta} (IL-1{beta}), IL-6, tumor necrosis factor {alpha} (TNF{alpha}), and ROS, and positively correlated with leptin and glutathione peroxidase (GPx). Multivariate regression analysis showed that stage and IL-6 were independent factors determining Hb values. This evidence suggests that anemia in epithelial ovarian cancer is common and its presence is related to stage of disease and markers of inflammation.


   Introduction
Top
 Abstract
 Introduction
Patients and methods
 Results
 Discussion
 References
 
Anemia is present in more than 30% of patients with epithelial ovarian cancer at the time of initial presentation. The severity of cancer-related anemia (CRA) has been associated with more aggressive tumors.1 Nevertheless, few studies have focused on the mechanisms of cancer-induced anemia.

CRA is typically normochromic, normocytic with a low reticulocyte count. Bone marrow iron stores are adequate or increased, but iron reutilization is impaired, as shown by normal or increased ferritin levels and low serum iron levels and iron binding capacity.2 In CRA, erythroid progenitor cells respond normally to erythropoietin (EPO), but EPO production is often not optimal for the level of anemia.3 The biologic and hematologic characteristics of CRA are similar to those observed in anemia occurring in chronic inflammatory diseases.4-7

Markers of chronic inflammation, commonly observed in patients with malignancy, are thought to relate to the stage of disease, to low performance status (PS), and to compromised nutritional status and weight loss.8-10 Inflammatory mediators, particularly cytokines (interleukin 6 [IL-6], tumor necrosis factor {alpha} [TNF{alpha}], and IL-1{beta}) have been recognized to play a key role in inducing anorexia, nausea/vomiting, and the severe energy metabolism disorders occurring in patients with advanced cancer. The release of proinflammatory cytokines in neoplastic patients is often associated with increased production of reactive oxygen species (ROS) (H2O2 and ) either as a component of their immune response or as a consequence of increased metabolism.8,11,12 We have shown that in patients with advanced cancer the inflammatory response is inversely related to leptin levels, a marker of nutritional status.9,10,13 Thus, the presence of inflammation in patients with cancer may account for profound physiologic changes, including those metabolic changes resulting in cachexia and, possibly, anemia.

Several in vitro and in vivo studies demonstrated that high levels of proinflammatory cytokines and increased oxidative stress contribute both to the development of anemia and to the resistance to recombinant human EPO.14 Therefore, we asked, in the absence of blood loss, myelosuppressive therapy, and bone metastases, whether the same inflammatory substances, known for their role in the onset of cachexia syndrome, could account for the development of CRA.

Many studies have shown a correlation between inflammation, elevated circulating cytokines, and anemia in mice and in patients with chronic inflammation or end-stage renal disease,15 but direct evidence for this association in a wide population of patients with cancer is lacking. Accordingly, we assessed a population of previously untreated women with epithelial ovarian carcinoma to determine the relationship of hemoglobin (Hb) and parameters of inflammatory stress, including cytokines and ROS.


   Patients and methods
Top
 Abstract
 Introduction
 Patients and methods
Results
 Discussion
 References
 
The study, approved by the local Ethical Committee and by the Institutional Review Board, was carried out at the Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia; and the Department of Obstetrics and Gynecology and Department of Medical Oncology of the University of Cagliari, Cagliari, Italy. The study was performed in accordance with the Declaration of Helsinki. All subjects participated in the study as volunteers, after signing an informed written consent.

The subjects included in the study were 91 women with epithelial ovarian cancer (mean age, 62.1 years; range, 45-81 years) (study group), and 95 healthy women matched for age, weight, and height (mean age, 61 years; range, 46-78 years) (control group). The clinical characteristics of the patients with epithelial ovarian cancer and the control subjects are reported in Table 1. The diagnosis of ovarian cancer was histologically confirmed in all patients. The stage of ovarian cancer was carried out in accordance to the International Federation of Gynecology and Obstetrics classification system. At the time of study, no patient had received surgery, radiotherapy, chemotherapy, or other medical interventions. No subject included in the study had evidence of infections, gastrointestinal disease, vaginal bleeding, or hemolysis.


View this table:
[in this window]
[in a new window]
  		Table 1.. Clinical characteristics of patients with epithelial ovarian cancer

 
In all subjects the body mass index (BMI) was calculated as weight (in kg)/height (in m2), whereas the PS was quantified using the World Health Organization–approved Eastern Cooperative Oncology Group (ECOG) PS scale.16 This scale evaluates 3 dimensions of health status simultaneously (activity, work, self-care), and scores range from 0 (fully active) to 5 (dead).

In all subjects a blood sample was obtained from venipuncture of an antecubital vein at 8 AM after overnight fasting. The blood samples were collected in tubes with clot-activating factor and centrifuged immediately after collection, and serum was stored at -20°C until assayed. In each serum sample the levels of Hb, C-reactive protein (CRP), fibrinogen (Fbg), proinflammatory cytokines (IL-6, IL-1, TNF{alpha}), IL-2, and leptin were analyzed. ROS and antioxidant enzymes (glutathione peroxidase [GPx], and superoxide dismutase [SOD]) were assessed on fresh heparinized blood samples.

Assessment of Hb, hematologic, and iron parameters (RBC, MCV, MCHC, absolute reticulocyte count, serum iron, and ferritin)

All control subjects and patients with ovarian cancer were subjected to the following analysis: Hb concentration, red blood cell (RBC) count, mean cell volume (MCV), mean cell hemoglobin concentration (MCHC), reticulocyte count (percentage and absolute number), concentration of serum iron, and ferritin. Red blood cell count and reticulocyte analysis were undertaken using our routine blood counting analyser (Coulter Gen-S; Beckman Coulter, Fullerton, CA).

All laboratory examinations were performed locally according to good clinical practice. The coefficient of variation for these methods, over the range of measurement, was less than 5% as established by routine quality control procedures.

Assessment of CRP and Fbg

Routine laboratory analysis of CRP and Fbg concentration was carried out. The coefficient of variation for these methods, over the range of measurement, was less than 5% as established by routine quality control procedures.

Serum levels of proinflammatory cytokines (IL-1{beta}, IL-6, and TNF{alpha}) and leptin.

Proinflammatory cytokines (IL-1{beta}, IL-6, and TNF{alpha}) were detected by a "sandwich" enzyme-linked immunosorbent assay (ELISA) test (Biosource Europe SA, Nivelles, Belgium, for IL-6 and TNF{alpha}; Immunotech SA, Marseille, France for IL-1{beta}) using monoclonal antibodies for 2 different epitopes of the cytokine molecule. The absorbance of the sample at 450 nm for IL-6 and TNF{alpha} and at 405 nm for IL-1{beta} was measured with a spectrophotometer (Sirio; Seac, Florence, Italy). A standard curve was prepared by plotting the absorbance value of the standards versus corresponding concentrations. The concentration of the cytokine in the sample was determined by extrapolating from the standard curve. Intra-assay variations were 3% for IL-6 and 6% for TNF{alpha} and IL-1{beta}. Interassay variations were 7% for TNF{alpha}, 8% for IL-6, and 7% for IL-1{beta}. The results were expressed in picogram per milliliter. Serum levels of leptin were measured by a double-antibody "sandwich" ELISA test (DRG Instruments, Marburg, Germany) by using a monoclonal antibody specific for human leptin. The absorbance was measured at 450 ± 10 nm in a plate reader. The intra-assay and interassay variations were 5% and 7%, respectively. The results were expressed in nanogram per milliliter. More details of the techniques used are described in our previous reports.9,10

Assessment of blood levels of reactive oxygen species (ROS) and antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD)

The ROSs were determined using the FORt test (Callegari, Parma, Italy), which is based on the Fenton reaction. When a 20-µL blood sample was dissolved in an acidic buffer, the hydroperoxides reacted with the transition metal ions liberated from the proteins in the acidic medium and were converted to alkoxy- and peroxy-radicals. The radical species produced by the reaction, which are directly proportional to the quantity of lipid peroxides present in the sample,17,18 interact with an additive (phenylendiamine derivative) that forms a radical molecule evaluable by spectrophotometer at 505 nm (Form CR 2000; Callegari). Results are expressed as FORT U (Fort units) whereby 1 FORT U corresponds to 0.26 mg/L H2O2.18

Erythrocyte GPx and SOD activity was measured using a commercially available kit (Ransod; Randox Lab, Crumlin, United Kingdom). The results obtained are expressed in unit per liter (U/L) of whole blood (GPx) and in unit per milliliter (U/mL) of whole blood (SOD).8

Statistical analysis

Data are represented as means plus or minus standard deviation unless otherwise stated. The significance of the difference between the mean values of patients with cancer divided according to stage of disease (stages I-II and stages III-IV) and control group was determined using 2-tailed Student t test or its nonparametric equivalent, the Mann-Whitney U test, when appropriate. Correlations between Hb and clinical (stage of disease, ECOG PS, weight, and BMI) and laboratory variables (CRP, Fbg, IL-1{alpha}, IL-6, TNF{alpha}, leptin, ROS, SOD, and GPx) were tested using 2-sided Spearman rank correlation analysis, using Bonferroni correction for multiple tests. Significant relationships were then examined by multivariate linear regression analysis against Hb (dependent variable). Results were regarded as significant if P values were .05 or less.


   Results
Top
 Abstract
 Introduction
 Patients and methods
 Results
Discussion
 References
 
Hb and other hematologic parameters (RBC, MCV, MCHC, reticulocyte count, serum iron, and ferritin)

Among patients with epithelial ovarian cancer, patients at stages III to IV of disease showed significantly lower Hb levels compared with control group subjects (P < .001) and patients at stages I to II (P < .001). In patients at stages I to II of disease, in turn, Hb levels were not significantly different from control subjects (Table 2; Figure 1). As for other hematologic and iron parameters, it is to be noted that patients with stages III to IV epithelial ovarian cancer had a significantly lower RBC and reticulocyte counts, lower MCV, lower serum iron levels, and significantly higher serum ferritin levels in comparison to healthy individuals and patients at stages I to II (Table 2).


View this table:
[in this window]
[in a new window]
  		Table 2.. Evaluation of Hb, hematologic variables (RBCs, MCV, MCHC, absolute reticulocyte count), and iron parameters (serum iron and ferritin) in 95 control subjects and in 91 patients with epithelial ovarian cancer according to stage

 



View larger version (16K):
[in this window]
[in a new window]
  		Figure 1.. Hemoglobin levels in 95 control subjects and 91 patients with epithelial ovarian cancer according to stage. Hemoglobin levels were significantly lower in patients with ovarian cancer than in control subjects (P < .001). Patients with stages III to IV cancer had significantly lower hemoglobin levels than patients with stages I to II (P < .001). Significance was calculated by 2-sided Student t test. The box plots in the figure represent columns of data as boxes whose extents indicate the 25th and 75th percentiles of the column. The line inside the box represents the median. + marks the value of the mean. Capped bars indicate the minimum and maximum value observed.

 
CRP and Fbg in patients with epithelial ovarian cancer and control subjects

CRP and Fbg levels were significantly higher in patients with epithelial ovarian cancer at stages III to IV of disease in comparison to the control group subjects (P < .001) and patients at stages I to II of disease (P < .001). In patients at stages I to II of disease, in turn, CRP and Fbg levels were not significantly different from control subjects (Table 3; Figure 2).


View this table:
[in this window]
[in a new window]
  		Table 3.. Evaluation of laboratory parameters of inflammation and oxidative stress in 95 control subjects and in 91 patients with epithelial ovarian cancer according to stage

 
Serum levels of proinflammatory cytokines (IL-1{beta}, IL-6, and TNF{alpha}) and leptin in patients with epithelial ovarian cancer and control subjects

Serum levels of IL-1{beta} and TNF{alpha} were significantly higher in patients with advanced epithelial ovarian cancer (stages III-IV) compared with control subjects (P < .001) and patients with stages I to II disease (P = .007, P < .001, and P = .003, respectively). Patients at stages I to II of disease, in turn, did not show significantly different levels of IL-1{beta} and TNF{alpha} compared with control subjects. Levels of IL-6 were significantly higher in patients with epithelial ovarian cancer both in stages III to IV and stages I to II compared with control subjects (P < .001, for both) (Table 3; Figure 3). Serum leptin levels were significantly lower in patients with stages III to IV epithelial ovarian cancer in comparison to control subjects (P < .001) and patients in stages I to II (P < .009). In patients with epithelial ovarian cancer at stages I to II of disease, in turn, leptin levels were not significantly different from control subjects (Table 3; Figure 3).



View larger version (13K):
[in this window]
[in a new window]
  		Figure 2.. Serum levels of CRP and Fbg in 95 control subjects and 91 patients with epithelial ovarian cancer according to stage. Serum levels of CRP and Fbg were significantly lower in patients with cancer than in control subjects (P < .001 and P = .04, respectively). Moreover, patients with stages III to IV ovarian cancer had significantly higher CRP and Fbg levels than did patients with stages I to II (P < .001, for both). Significance was calculated by 2-sided Student t test. The box plots in the figure represent columns of data as boxes whose extents indicate the 25th and 75th percentiles of the column. The line inside the box represents the median. + marks the value of the mean. Capped bars indicate the minimum and maximum value observed.

 



View larger version (9K):
[in this window]
[in a new window]
  		Figure 3.. Serum levels of IL-1{beta}, IL-6, TNF{alpha}, and leptin in 95 control subjects and 91 patients with epithelial ovarian cancer according to stage. Patients with ovarian cancer showed significantly higher (P < .001) serum levels of IL-1{beta}, IL-6, and TNF{alpha} and lower leptin in comparison with control subjects. Moreover, patients with stages III to IV cancer showed higher levels of IL-1{beta}, IL-6, and TNF{alpha} and lower levels of leptin in comparison to patients with stages I to II. Significance was calculated by 2-sided Student t test, while for leptin the significance was calculated using the Mann-Whitney U test. The box plots in the figure represent columns of data as boxes whose extents indicate the 25th and 75th percentiles of the column. The line inside the box represents the median. + marks the value of the mean. Capped bars indicate the minimum and maximum value observed.

 
Blood levels of ROS and antioxidant enzymes GPx and SOD in patients with epithelial ovarian cancer and in control subjects

Blood levels of ROS were significantly higher in patients with epithelial ovarian cancer (both stages III-IV and stages I-II) compared with control subjects (P < .001). Blood levels of GPx and SOD were significantly lower in patients with stages III to IV epithelial ovarian cancer compared with control subjects (P < .001, for both) and patients in stages I to II (P < .001 for GPx and P = .028 for SOD). In patients with stages I to II of disease, GPx and SOD were not significantly different from control subjects (Table 3; Figure 4).

Correlation between hemoglobin, clinical parameters (stage of disease and ECOG PS) and serum levels of proinflammatory cytokines, CRP, Fbg, ROS, and antioxidant enzymes (SOD and GPx)

A significant negative relationship was found between Hb levels and stage of disease (r = -0.84, P < .001) and ECOG PS (r = -0.82, P < .001). A significant positive relationship was found between Hb levels and weight (r = 0.36, P = .022) and BMI (r = 0.48, P = .001). As for laboratory variables, a significant negative correlation was found between Hb levels and CRP (r = -0.73, P = < .001), Fbg (r = -0.67, P < .001), IL-1{beta} (r = -0.50, P = .001), IL-6 (r = -0.78, P < .001), TNF{alpha} (r = -0.52, P = .001), and ROS (r = -0.73, P < .001) levels. A significant positive correlation was found between Hb levels and serum levels of leptin (r = 0.455, P = .001) and blood levels of GPx (r = 0.62, P < .001). SOD levels did not show a significant correlation with Hb levels (r = 0.19, P = .245) (Table 4). Significant relationships were further included in multivariate regression analysis. With regard to Hb (dependent variable), the evaluation revealed that only stage (coefficient = -0.5906, P = .035) and IL-6 levels (coefficient = -0.0230, P = 0.046) were independent factors predicting Hb levels (Table 5). Moreover, we also tested whether IL-6 was a predictive variable of the other proinflammatory markers: single regression analysis showed that IL-6 was significantly positively correlated with IL-1{beta} (P = .020), CRP (P < .001), Fbg (P = .001), and ROS (P < .001) (Figure 5).


View this table:
[in this window]
[in a new window]
  		Table 4.. Correlation of Hb levels with clinical parameters (stage, weight, BMI) and markers of chronic inflammation and oxidative stress in 91 patients with epithelial ovarian cancer

 


View this table:
[in this window]
[in a new window]
  		Table 5.. Multiple regression analysis of stage and laboratory variables with regard to Hb levels in 91 epithelial ovarian cancer patients

 



View larger version (11K):
[in this window]
[in a new window]
  		Figure 4.. Blood levels of ROS, GPx, and SOD in 95 control subjects and 91 patients with epithelial ovarian cancer according to stage. ROS levels were significantly higher (P < .001), while GPx and SOD activities were significantly lower in patients with cancer than in control subjects (P < .001). P was calculated by 2-sided Student t test. The box plots in the figure represent columns of data as boxes whose extents indicate the 25th and 75th percentiles of the column. The line inside the box represents the median. + marks the value of the mean. Capped bars indicate the minimum and maximum value observed.

 

   Discussion
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
References
 
The study was designed to determine whether those factors that have been demonstrated to play a critical role in the onset of cachexia, weight loss, and impairment of performance status are also involved in the development of anemia. To test this hypothesis, 91 previously untreated patients with epithelial ovarian cancer were evaluated. As expected, Hb levels were lower in patients than in appropriately matched control subjects. Furthermore, as previously shown by Obermair et al,1 Hb concentrations were inversely related to stage of disease and severity of chronic inflammatory status. In our study, advanced epithelial ovarian cancer (stages III-IV) showed anemia similar to anemia of inflammation (also referred to as anemia of chronic disease), which is characterized by normocytic or microcytic iron-refractory anemia, low serum iron, and preserved bone marrow iron.19 The lowest Hb levels associated with the highest concentrations of markers of inflammation, such as proinflammatory cytokines (IL-6, IL-1{beta}, TNF{alpha}), CRP, and Fbg, and with the lowest leptin levels. Statistical analysis confirmed that Hb inversely correlated with stage and ECOG PS, proinflammatory cytokines (IL-6, IL-1{beta}, TNF{alpha}), CRP, Fbg, and ROS but positively correlated with leptin and GPx. By multivariate regression analysis, only stage of disease and IL-6 levels were independent factors in determining Hb levels.

Van der Zee et al20 demonstrated that higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.

A central role for IL-6 in the induction of both CRA and the anemia of inflammatory disease has been recently demonstrated. A specific role for IL-6 in the pathogenesis of anemia has been suggested by Ershler21 who has found an increased level of IL-6 with advanced age, presumably because of an age-acquired dysregulation, and a corresponding increased prevalence of anemia. Moreover, several researchers22,23 have demonstrated that IL-6 is both necessary and sufficient for the induction of hepcidin, an iron regulatory hormone responsible for inflammation-induced iron disutilization resulting in the anemia associated with acute and chronic infections,24,25 chronic kidney disease,26 and presumably neoplastic disease.27



View larger version (31K):
[in this window]
[in a new window]
  		Figure 5.. Single regression analysis between IL-6 and markers of chronic inflammation and oxidative stress. IL-6 was significantly correlated to (A) IL-1{beta} (P = .020), (B) C-reactive protein (P < .001), (C) reactive oxygen species (ROS; P < .001), and (D) fibrinogen (Fbg; P = .001). The central straight line corresponds to the best-fit linear regression line. The two curved lines surrounding the best-fit line define the 95% confidence interval of the regression line. The graphs also show the prediction interval (the curves defining the prediction interval are further from the regression line than the confidence lines).

 
The pattern of IL-6 and Hb found in our study in patients with ovarian cancer needs to be further evaluated for other types of cancer. In fact, it could be linked with a specific production of IL-6 by ovarian cancer cells and not a marker of inflammation. Higher serum levels of IL-6 have been found in patients with ovarian cancer than in patients with other malignancies,28 and levels have been shown to correlate with extent of disease29 and unfavorable clinical outcome.30 However, in our previously published studies, we demonstrated that tumor-associated mononuclear cells (lymphocytes and monocytes) from neoplastic effusions and peripheral blood were able to produce high amounts of IL-6 and IL-211,31 and that increased IL-6 levels were associated with CRP and aspecific/ineffective immune response.12 As yet it is not clear whether increased IL-6 levels in patients with advanced ovarian cancer are produced by the tumor itself or mainly by host tissues.

Of note, in the current study we demonstrated a significant positive correlation between IL-6 and other markers of inflammation and oxidative stress (IL-1{beta}, CRP, Fbg, and ROS). Thus, high serum levels of IL-6 may be considered an indicator of the inflammatory and pro-oxidative status of patients with epithelial ovarian cancer.

The study did not demonstrate the mechanism through which the high levels of inflammatory mediators could induce CRA. However, several studies, in addition to those cited earlier, showed that proinflammatory cytokines blunt EPO response to anemia and impair erythroid colony formation in response to EPO.32-34 Additionally, proinflammatory cytokines IL-1, IL-6, TNF{alpha}, and the acute-phase proteins impair iron metabolism, inhibiting the reticuloendothelial iron stores with low iron circulating levels.35-37 Disorder in iron reutilization characterizes also CRA.38

The presence of proinflammatory cytokines in patients with neoplasms has been associated with increased production of ROS (H2O2 and ) either as a reflection of inflammation or as a consequence of their metabolic effects.8,11,12 As shown by our previous8,39 and current study, in patients with advanced ovarian cancer the presence of chronic inflammation is tightly correlated with markers of oxidative stress. Several studies demonstrated that ROSs are capable of inhibiting the production of EPO from kidney tissue.40

The lower leptin levels found in our patients with advanced ovarian cancer may be the consequence of cancer-related nutritional inadequacy and impaired energy metabolism or the direct result of high levels of IL-6 or the other cytokines.9,10 Takeda et al41 hypothesized that nutritional status, probably through leptin action, may affect erythropoiesis and demonstrated that BMI and leptin were inversely correlated with the recombinant human EPO (rHuEPO) dose required in patients receiving hemodialysis. Indeed, in vitro studies have suggested that leptin plays a role in enhancing erythropoiesis,42 but, certainly, this hypothesis needs more definitive analysis.

The results we have presented suggest that anemia in patients with epithelial ovarian cancer is, at least in part, the consequence of cancer-related chronic inflammation. Cancer-related anemia must be recognized as a constitutional feature of patients with advanced neoplasms and not necessarily as just a consequence of antineoplastic treatments. Indeed, it has been widely demonstrated that CRA is associated with poor response to treatment and decreased survival,43 and with a decline in energy and activity levels, quality of life, and cognitive functions.44 An increased understanding of the pathogenesis of CRA may help identify the most appropriate treatment strategies.22,45


   Footnotes
 
Submitted January 12, 2005; accepted March 10, 2005.

Prepublished online as Blood First Edition Paper, March 17, 2005; DOI 10.1182/blood-2005-01-0160.

Supported by Associazione sarda per la ricerca in oncologia ginecologica ONLUS.

A.M. designed the research, performed the research, analyzed the data, and wrote the paper; C.M. designed the research, performed the research, contributed vital new reagents or analytical tools, analyzed the data, and wrote the paper; D.M., M.C.M., M.R.L., and G.G. performed the research, contributed to patient enrollment and assessment, and collected the data; R.S. performed the research and contributed to the analytical tools; and G.B.M. and G.M. contributed to the design of the research and wrote the paper.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

Reprints: Antonio Macciò, Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, Italy; e-mail: a.maccio{at}tin.it.


   References
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
 References
 

  1. Obermair A, Handisurya A, Kaider A, et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998;15: 726-731.

  2. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28: 1-6.[Medline] [Order article via Infotrieve]

  3. Nowrousian MR, Kasper C, Oberhoff C. Pathophysiology of cancer-related anemia. In: Smythe J, ed. RHu Erythropoietin in Cancer Supportive Treatment. New York, NY: Marcel Dekker; 1996: 13-34.

  4. Spivak JK. The blood in systemic disorders. Lancet. 2000;355: 1707-1712.[CrossRef][Medline] [Order article via Infotrieve]

  5. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect Dis. 1997;25: 888-895.[Medline] [Order article via Infotrieve]

  6. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341: 1986-1995.[Free Full Text]

  7. Erslev AJ. Anemia of chronic disease. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology. New York, NY: McGraw-Hill Professionals; 2000: 481-488.

  8. Mantovani G, Macciò A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer. 2002;98: 84-91.[CrossRef][Medline] [Order article via Infotrieve]

  9. Mantovani G, Macciò A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med. 2000;78: 554-561.[CrossRef][Medline] [Order article via Infotrieve]

  10. Mantovani G, Macciò A, Madeddu C, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med. 2001;79: 406-414.[CrossRef][Medline] [Order article via Infotrieve]

  11. Mantovani G, Macciò A, Pisano M, et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int J Cancer. 1997;71: 724-731.[CrossRef][Medline] [Order article via Infotrieve]

  12. Macciò A, Lai P, Santona MC, et al. High serum levels of soluble IL-2 receptor, cytokines, and C-reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69: 248-252.[CrossRef][Medline] [Order article via Infotrieve]

  13. Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine. 2002;19: 21-26.[CrossRef][Medline] [Order article via Infotrieve]

  14. Means RT Jr. The anemia of infection. Baillieres Best Pract Res Clin Haematol. 2000;13: 151-162.[Medline] [Order article via Infotrieve]

  15. Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100: 3776-3781.[Abstract/Free Full Text]

  16. Oken MM, Creech RH., Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5: 649-655.[Medline] [Order article via Infotrieve]

  17. Alberti A, Bolognini L, Macciantelli D, et al. The radical cation of N, N-Diethyl-para-Phenylendiamine: a possible indicator of oxidative stress in biological samples. Res Chem Intermed. 2000;26: 253-267.[CrossRef]

  18. Cornelli U, Terranova R, Luca S, et al. Bioavailability and antioxidant activity of some food supplements in men and women using the D-Roms test as a marker of oxidative stress. J Nutr. 2001;131: 3208-3211.[Abstract/Free Full Text]

  19. Means RT. Hepcidin and anaemia. Blood Rev. 2004;18: 219-225.[CrossRef][Medline] [Order article via Infotrieve]

  20. van der Zee AG, de Cuyper EM, Limburg PC, et al. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995;75: 1004-1009.[CrossRef][Medline] [Order article via Infotrieve]

  21. Ershler WB. Biological interaction of aging and anemia: a focus on cytokines. J Am Geriatr Soc. 2003;51: S18-S21.[CrossRef][Medline] [Order article via Infotrieve]

  22. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004;113: 1251-1253.[CrossRef][Medline] [Order article via Infotrieve]

  23. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113: 1271-1276.[CrossRef][Medline] [Order article via Infotrieve]

  24. Nemeth E, Valore EV, Territo M, et al. Hepcidin: a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101: 2461-2463.[Abstract/Free Full Text]

  25. Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11: 251-254.[CrossRef][Medline] [Order article via Infotrieve]

  26. Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant. 2004;19: 521-524.[Free Full Text]

  27. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. Prepublished on October 12, 2004, as DOI 10.1182/blood-2004-08-3375. (Now available as Blood. 2005;105: 1797-1802).[Abstract/Free Full Text]

  28. Nash MA, Ferrandina G, Gordinier M, et al. The role of cytokines in both the normal and the malignant ovary. Endocr Relat Cancer. 1999;6: 93-107.[Abstract]

  29. Berek JS, Chung C, Kald K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164: 1038-1042.[Medline] [Order article via Infotrieve]

  30. Scambia G, Testa U, Benedetti Panici P, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer. 1995;71: 354-356.[Medline] [Order article via Infotrieve]

  31. Mantovani G, Macciò A, Versace R, et al. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. J Mol Med. 1995;73: 409-416.[Medline] [Order article via Infotrieve]

  32. Means RT Jr. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells. 1995;13: 32-37.[Medline] [Order article via Infotrieve]

  33. Kuzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92: 1684-1688.[CrossRef][Medline] [Order article via Infotrieve]

  34. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients whit the anemia of cancer. N Engl J Med. 1990;322: 1689-1692.[Abstract]

  35. Alvarez-Hernandez X, Liceaga J, McKay IC, et al. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest. 1989;61: 319-322.[Medline] [Order article via Infotrieve]

  36. Rogers JT. Ferritin translation by interleukin-1 and interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood. 1996;87: 2525-2537.[Abstract/Free Full Text]

  37. Konijn AM, Carmel N, Levy R, et al. Ferritin synthesis in inflammation: mechanisms of increased ferritin synthesis. Br J Hematol. 1981;49: 361-370.[Medline] [Order article via Infotrieve]

  38. Denz H, Huber P, Landmann R, et al. Association between the activation of macrophages, changes of iron metabolism and the degree of anemia in patients with malignant disorders. Eur J Haematol. 1992;48: 244-248.[Medline] [Order article via Infotrieve]

  39. Mantovani G, Macciò A, Madeddu C, et al. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res. 2003;37: 213-223.[CrossRef][Medline] [Order article via Infotrieve]

  40. Numcke I, Schneider B, Fandrey J, et al. Effect of pro- and antioxidative compounds on renal production of erythropoietin. Endocrinology. 1999;140: 641-645.[Abstract/Free Full Text]

  41. Takeda A, Toda T, Shinohara S, et al. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin. Am J Kidney Dis. 2002;40: 104-109.[CrossRef]

  42. Gainsford T, Willson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A. 1996;93: 14564-14568.[Abstract/Free Full Text]

  43. Munstedt K, Kovacic M, Zygmunt M, et al. Impact of hemoglobin levels before and during chemotherapy on survival of patients with ovarian cancer. Int J Oncol. 2003;23: 837-843.[Medline] [Order article via Infotrieve]

  44. Tchekmedian NS. Anemia in cancer patients: significance, epidemiology and current therapy. Oncology. 2002;16: 17-24.

  45. Stenvinkel P. Anaemia and inflammation: what are the implications for the nephrologist? Nephrol Dial Transplant. 2003;18: 7-22.[Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
J. L. Spivak, P. Gascon, and H. Ludwig
Anemia Management in Oncology and Hematology
Oncologist, September 1, 2009; 14(suppl_1): 43 - 56.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Mantovani
Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
Ann. Onc., July 1, 2008; 19(7): 1355 - 1355.
[Full Text] [PDF]

Home page
 J. Epidemiol. Community HealthHome page
K. Heikkila, S. Ebrahim, and D. A Lawlor
A systematic review of the association between circulating concentrations of C reactive protein and cancer
J Epidemiol Community Health, September 1, 2007; 61(9): 824 - 833.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
X. Zhang, D. P. Sejas, Y. Qiu, D. A. Williams, and Q. Pang
Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence
J. Cell Sci., May 1, 2007; 120(9): 1572 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. N. Roy, H. H. Mak, I. Akpan, G. Losyev, D. Zurakowski, and N. C. Andrews
Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Blood, May 1, 2007; 109(9): 4038 - 4044.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. P. Sejas, R. Rani, Y. Qiu, X. Zhang, S. R. Fagerlie, H. Nakano, D. A. Williams, and Q. Pang
Inflammatory Reactive Oxygen Species-Mediated Hemopoietic Suppression in Fancc-Deficient Mice
J. Immunol., April 15, 2007; 178(8): 5277 - 5287.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-01-0160v1
106/1/362    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macciò, A.
Right arrow Articles by Mantovani, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macciò, A.
Right arrow Articles by Mantovani, G.
Related Collections
Right arrow Neoplasia
Right arrow Red Cells
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020